AZNCF News and Press, AstraZeneca Plc From 01/09/23

Summary The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance. This article will analyze the 10 largest pharmaceuticals and determine where the strongest pipelines lie. Introducti...

Summary FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform. The company has some early data that looks good. 4D Molecular Therapeutics ( FDMT ) is a gene therapy developer that’s remained pr...

Summary Japan just approved three drugs against cancer and leukemia. AstraZeneca increased its 2022 guidance. As already mentioned, premium pipelines deserve a premium valuation. The company is confirming a positive trajectory both in its internal R&D area as well as inorganical...

Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...

Summary Almost 60 percent of VEU’s AUM is invested in four sectors - ICT, financial, industrial, and healthcare. The fund generates decent yield and total returns. The strong US dollar, high sustained interest rate by the Fed, and slowing global economic growth are expected to we...

Summary On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company. Madrigal Pharmaceuticals stock is up 4x: what you should do now. I have been bullish on Madrigal ( MDGL ) since 20...

Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...

Summary The IOO ETF is mostly just a value weighted US portfolio, with European exposures consisting primarily of healthcare and consumer staple exposures. We think geopolitics is the most important factor, and the US is in a great position eating Europe's lunch. America continues t...

Summary Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month. Tango Therapeutics&#x...

AstraZeneca PLC (AZN) Q3 2022 Earnings Conference Call November 10, 2022 06:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO David Fredrickson - Exec...